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This study evaluated the efficacy and safety of three doses of
botulinum toxin A (BTX-A; Dysport®) in 125 patients (mean
age 5.2 years, SD 2; 54% male)with dynamic equinus
spasticity during walking. Participants were randomized to
receive Dysport (10, 20, or 30 units/kg) or placebo to the
gastrocnemius muscle of both legs. Muscle length was
calculated from electrogoniometric measurements and the
change in the dynamic component of gastrocnemius
shortening at four weeks was prospectively identified as the
primary outcome measure. All treatment groups showed
statistically significant decreases in dynamic component
compared with placebo at 4 weeks. Mean improvement in
dynamic component was most pronounced in the 20 units/kg
group, being equivalent to an increase in dorsiflexion with the
knee extended at 19 ,˚ and was still present at 16 weeks. The
safety profile of the toxin appears satisfactory. 
Since the first descriptions of the benefit of botulinum toxin A
(BTX-A) for the treatment of spasticity in children with cere-
bral palsy (CP; Koman et al. 1993, 1994; Cosgrove et al. 1994),
its use has become routine in many centres. In a number of
controlled studies, beneficial effects of toxin treatment, over
and above the placebo effects, have been reported for lower-
limb spasticity associated with CP (Chutorian and Root 1995;
Corry et al. 1997, 1999; Sutherland et al. 1999; Koman et al.
2000). In addition, the beneficial effect of BTX-A has been
demonstrated when compared with splinting and stretching
casts (Corry et al. 1998, Flett et al. 1999).
In several different studies, toxin injections have been
administered to a variety of muscles in the lower limb,
including hamstrings (Corry et al. 1999), iliopsoas (Heinen
et al. 1997b), adductors (Carr et al. 1998), and tibialis poste-
rior (Sanchez-Carpintero and Narbona 1997, Mousny and
Allington 1999), in addition to muscles of the upper limb
(Corry et al. 1997, Friedman et al. 2000). However, in most
studies in children with CP, injections have been made into
the gastrocnemius muscle (Koman et al. 1993, 1994; Cosgrove
et al. 1994; Chutorian and Root 1995; Corry et al. 1998; Flett et
al. 1999; Eames et al. 1999; Sutherland et al. 1999; Boyd et al.
2000; Koman et al. 2000).
To assess the outcome of the treatment at the level of
‘body structure and function’ (as defined by the World Health
Organization 1999), many different measures have been used,
including electromyography (Hesse et al. 1994, Heinen et al.
1997b), goniometry (Cosgrove et al. 1994, Denislic and Meh
1995, Heinen et al. 1997a), muscle torque (Corry et al.
1997), the Ashworth scale (Calderon-Gonzalez et al. 1994,
Denislic and Meh 1995, Heinen et al. 1997b) and general gait
analysis (Cosgrove et al. 1994, Sutherland et al. 1999). Eames
and colleagues (1999) investigated the effect of BTX-A injec-
tions on muscle length and showed that a single injection
into the calf led to an increase in gastrocnemius muscle
length during gait. They also defined the ‘dynamic compo-
nent’ of muscle shortening as the difference between the
maximum gastrocnemius length recorded during passive
examination and the maximum length recorded during
walking. They showed a linear relationship between this
dynamic component and the response to BTX-A injection.
Consequently, at the level of ‘body structure and function’
this is probably the most sensitive indicator of a response to
BTX-A injections.
Although it is clear that the toxin has a beneficial effect at
this level, it is also important to evaluate its impact at the
level of ‘activity’ (World Health Organization 1999). To mea-
sure this, some of the early studies used the Physician’s
Rating Scale (Koman et al. 1993, 1994; Denislic et al. 1995).
Recently, however, the Gross Motor Function Measure
(GMFM; Russell et al. 1989) has become more widely used as
an outcome measure for children with CP. In three studies
this has been used to assess the benefit of BTX-A injections
(Flett et al. 1999, Yang et al. 1999, Mall et al. 2000). The
Paediatric Evaluation of Disability Inventory (Haley et al.
1992) and the WeeFIM (Msall et al. 1994) could also be used,
but these span both ‘activity’ and ‘participation’.
Despite nearly 10 years of use in clinical practice, there is
little scientific evidence for an optimum dose of BTX-A in this
condition. In previous studies, the doses of Dysport® have
varied between 5 units/kg body weight (Cosgrove et al. 1994,
Heinen et al. 1997b) and 30 units/kg (Heinen et al. 1997b).
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In 1998, in a consensus paper, Carr and colleagues (1998)
recommended a dose in the range 0.25 to 35 units/kg, with
no more than 200 units per site, and a maximum total dose of
900 to 1000 units per treatment. More recently Bakheit and
coworkers (2001) suggested that doses of up to 1000
units/kg do not increase susceptibility to adverse events but
were not able to make any definitive conclusions about effi-
cacy. Only one published study (Wissel et al. 1999) has inves-
tigated the effects of different doses of BTX-A, but this study
was not placebo controlled.
Method
ETHICAL CONSIDERATIONS
This study was conducted in accordance with the Declaration
of Helsinki and its amendments, and in compliance with the
guidelines for Good Clinical Practice. It was approved by
the National and Local Research Ethics Committee for each of
the 12 participating European centres. The study was fully
explained to the parent(s) or guardian(s) and all gave written
consent before any study-specific assessments were per-
formed. Where possible, the study was also explained to the
children themselves.
PARTICIPANTS
Participants were identified from those attending one of six
centres in the UK, one in Ireland, and five in Poland (as iden-
tified in the affiliations of the authors). Selection criteria
were defined in advance of the start of recruitment. Eligible
participants (of either sex) were aged 2 to 9 years, weighed
10 to 25kg, and were ambulatory (with or without orthoses
or walking aids), with a diagnosis of diplegic CP, a dynamic
component of more than 1.5% in at least one leg, and the
potential to benefit from administration of BTX-A to the gas-
trocnemius muscles of both legs. Participants were excluded
if they had received treatment with BTX-A within the 9
months before entry, previous phenol treatment for lower-
limb spasticity, or previous surgery on the muscles or liga-
ments of the lower limb. Those with valgus deformity of the
foot or excessive ankle dorsiflexion were also excluded,
because the model of gastrocnemius muscle length is not
necessarily valid in these participants. Participants having
used an investigational drug in the preceding 30 days, with a
generalized muscle activity disorder (e.g. myasthenia gravis),
or receiving aminoglycoside antibiotics or spectinomycin,
were also excluded.
INTERVENTIONS
Participants were randomized to receive either placebo or a
total dose of Dysport (Ipsen Ltd, Maidenhead, UK) of 10, 20
or 30 units/kg. Dysport was supplied in clear vials as a
freeze-dried white pellet containing clostridium botulinum
type A toxin–haemagglutinin complex. The placebo consist-
ed of the excipient alone. Study medication was supplied to
centres in individual patient packs, each containing indis-
tinguishable vials. Each pack contained either one (10
units/kg), two (20 units/kg), three (30 units/kg), or no active
vials (placebo group). All four vials were always used, and
the contents of each vial were reconstituted with 1.0ml of
sterile saline (0.9% w/v). The vial contents were drawn up
into a single syringe, giving a total of 4ml. A fraction of this
volume, determined by the weight of the patient (to the
nearest kilogram), was taken and made up to the final injec-
tion volume of 2ml with sterile saline (0.9% w/v), so that
0.5ml could be injected at two sites on the calf of each leg.
Patients were treated within 1 hour of reconstitution.
The sites of injection were at the junction of the proximal
quarter and the distal three-quarters of the gastrocnemius
muscle, determined by palpation of the femoral and cal-
caneal insertions. The site for injection was confirmed by
positioning the limb to produce the maximum stretch in the
gastrocnemius, inserting the needle and moving the distal
joint through its full range of movement. If positioned cor-
rectly, the needle remained at the angle of injection. A seda-
tive (e.g. midazolam) and/or a topical anaesthetic cream.
could be used before injection, as required.
Oral antispasticity medication, if it was taken before the
start of the study, was continued at the same dose through-
out the course of the study. Regular physiotherapy and the
use of walking aids and/or orthoses were also permitted, but
did not change throughout the study.
OBJECTIVES
The aims of this prospective, multicentre, double-blind,
placebo-controlled, dose-ranging study were to assess the
efficacy and safety of three different doses of Dysport (10, 20
and 30 units/kg body weight) in the treatment of dynamic
equinus spasticity in patients with CP. A full protocol was
written before recruitment was started. The primary efficacy
measure was identified in this as the change in dynamic com-
ponent at 4 weeks. Secondary outcome measures were also
recorded as described below. The primary safety measure
was an assessment of adverse events. The specific hypothe-
ses were that the different treatment groups showed differ-
ences from the placebo group. Data were also collected at 8
and 16 weeks to give an indication of the duration of the
effect.
OUTCOME MEASURES
Following Eames and colleagues (1999), the change in the
dynamic component of gastrocnemius shortening at 4 weeks
after injection was taken as the primary outcome measure of
efficacy. This was also measured at 8 and 16 weeks to monitor
the duration of response. The range of ankle movement on
passive examination, assessed at 4, 8, and 16 weeks, and the
change in GMFM, assessed at 4 and 16 weeks, were the sec-
ondary outcome measures of efficacy. The primary measure
of safety was the assessment of spontaneously reported
adverse incidents. All baseline measurements were made less
than 1 week before administration of the study medication.
Eames and colleagues (1999) measured the dynamic com-
ponent of gastrocnemius shortening by using 3-D gait analy-
sis. Not all participating centres had access to 3-D gait
analysis, so a custom-designed measurement system based
on the use of flexible electrogoniometers (Biometrics Ltd,
Cwmfelinfach, Gwent, UK) was produced. Standard M-180
units were used to measure knee angle; modified units, with
the distal end-block perpendicular to the sensor, were used
to measure ankle angle. Before performing any assessment,
all equipment was checked and calibrated. Patients were
barefoot and dressed in shorts to facilitate the correct posi-
tioning of the goniometers. The proximal knee goniometer
end-block was oriented along a line from the femoral epi-
condyle to the centre of the greater trochanter. The distal
knee end-block and proximal ankle end-block were both
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placed parallel to a line between the lateral malleolus and
the fibula head. The distal ankle end-block was aligned with
the plantar surface of the foot with a custom-made alignment
plate. The goniometers were connected to a K100 patient unit
and, via a cable, to the K100 desktop unit. Output was then fed
into a laptop computer. Customized software was written to
calculate muscle length as a function of the goniometer mea-
surements, based on the model of Eames et al. (1999), that cal-
culates gastrocnemius length as a function of participant
height and sagittal plane knee and ankle angles, measured by
3-D gait analysis.
Assessment of passive muscle length was made with the
patient supine and relaxed. With the knee extended, the calf
muscle was stretched by dorsiflexing the ankle until a maxi-
mum range of movement was obtained. A total of 180 values
were recorded over a 30-second period during which the
stretch was maintained. This was repeated twice (three tests
in total). Maximum passive muscle length was taken as the
30th highest value, from a total of 540, recorded from all
three tests. This was done to exclude the effects of artefacts in
the recorded data.
Data from each leg were collected and analyzed separate-
ly. Although the different legs of the same patient are clearly
not independent, the direct action to the toxin is (assumed
to be) local. The data presented below have been obtained
by treating each leg as a separate observation. The results
were, however, verified by alternative analyses summarising
the measurement across the two legs (e.g. average change
from baseline at week 4 across the two legs). Results from
these analyses were consistent with the result presented in
this paper.
Active muscle length was assessed during a 5-second walk
along a 10m walkway (300 values recorded). Only the mini-
mum walking aids necessary to ensure reasonable walking
ability (e.g. crutches) were permitted. Data from five walking
tests were captured. The captured data were filtered with a
five-sample moving-average filter and divided into gait
cycles. The maximum muscle length recorded during each
gait cycle was calculated. Maximum active muscle length was
taken as the fourth highest from the individual gait cycle.
This removed the effect of occasional abnormal gait cycles
showing uncharacteristically long muscle lengths. Data from
both legs were captured during all walks, but they were
processed separately for each side.
Although the dynamic component of Eames et al. (1999)
seems to be the most sensitive measure of the response to
injections into the gastrocnemius, the units in which it is
measured (difference in muscle length as a percentage of the
length in the anatomical position) are difficult to interpret clin-
ically. Clinicians are used to measuring the range of dorsiflex-
ion with the knee extended to assess gastrocnemius length,
and the model of Eames et al. (1999) was, therefore, used to
calculate the increase in this measurement, which would be
equivalent to a given change in the dynamic component. This
was carried out for dynamic components in the range 0 to 5%
and for participant height ranging from 500 to 1500mm.
All electrogoniometer data were checked for consistency
before the blinding codes were broken. Data from 5.2% (52 of
1002) leg assessments were considered unreliable for one or
more of the following reasons: missing goniometer measure-
ments, insufficient number of steps recorded, values outside
the physiological range, evidence of misplaced goniometers,
and electromagnetic interference. After the codes had been
broken, the proportion of unreliable data in each group was
found be similar (placebo 7.3%; Dysport 10 units/kg 4.2%;
Dysport 20 units/kg 5.4%; Dysport 30 units/kg 4.1%).
GMFM was assessed in accordance with the Gross Motor
Function Training Manual (Russell 1993). All assessors were
fully trained and accredited, and when possible the same
assessor performed the assessment at each clinic visit. The
total GMFM score was calculated and the scores for dimen-
sions D (standing) and E (walk/run/jump) were used to
obtain a goal total score.
At each clinic visit the investigator and the parents each
made a subjective functional assessment of gait, and rated
the patient’s response to treatment as ‘good’ (observable
and of functional benefit), ‘minimal’ (observable but not 
of functional benefit), ‘none’ (no observable change) or
‘worse’ (observable and to the detriment of the participant).
On completion of the study the investigator and the par-
ents made an overall assessment of efficacy by indicating
whether they believed that the patient had benefited from
treatment or not.
Occurrence of adverse events was monitored at each visit.
They were classified as ‘severe’ (incapacitating and prevent-
ing normal everyday activities), ‘moderate’ (sufficiently dis-
comforting to interfere with normal everyday activities), or
‘mild’ (easily tolerated by the patient, causing minimal dis-
comfort and not interfering with everyday activities).
SAMPLE SIZE
A power analysis based on the raw data used by Eames et 
al. (1999) was used to determine sample size. The SD of
decrease in dynamic component was 2.1% of anatomical
muscle length. To detect a difference between placebo (0.5%
decrease assumed) and the highest dose (2.0% decrease
assumed) at p<0.05 with 80% power, 30 patients per group
were required. A total sample size of 120 was therefore used.
No interim analyses or stopping rules were used.
RANDOMIZATION
The independent contractor (Penn Pharmaceuticals, Tredegar,
Gwent, UK) responsible for the preparation of study medica-
tion also produced the randomization scheme. A computer-
generated randomization scheme produced blocks of four
sequential preparation references such that each block allo-
cated each of four participants to the four study groups.
Because the preparations were indistinguishable, the ran-
domization scheme was concealed from everyone except the
contractor.
Separate subsets of this list were allocated to each centre.
After baseline assessments, eligible participants were allocat-
ed a number taken either from the beginning of the list (allo-
cated to their centre) or the end, depending on whether the
baseline dynamic component was greater than 4% in one or
both legs or not. This scheme thus ensured stratification by
centre and baseline component. If all blocks had been used,
an equal number of participants in each group would be guar-
anteed. Slight differences in numbers between groups reflect
the partial use of lists from different centres. Generation of the
allocation sequence and enrolment of participants were thus
completely independent. Assignment of patients to groups
was by a fixed protocol entirely dependent on the random-
ization scheme.
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BLINDING
As outlined above, only the independent contractor was
aware of group assignment. Participants, families, clinical
staff, and those responsible for assessors were thus all blind-
ed to this. Group assignments were not released until after
the final assessment, the completion of the statistical analysis
plan, and compilation of all data for that analysis.
STATISTICAL ANALYSES
The primary and secondary outcome variables were subjected
to statistical analysis, as were the two measures from which
the dynamic component is derived (maximum active and pas-
sive gastrocnemius length). The continuous variables (change
in dynamic component, maximum active and passive gas-
trocnemius length, maximum passive dorsiflexion with knee
extended or flexed, GMFM overall, and goal score) were ana-
lyzed by analysis of covariance. A model consisting of treat-
ment, baseline, centre and baseline dynamic component was
fitted to the data, with the baseline dynamic component cate-
gorized as either less than 4% or greater than 4%. The assump-
tions of normality and homogeneity of variance were assessed
by inspection of normal probability plots and residual plots.
Standardized residuals versus predicted values and standard-
ized residuals versus covariate plots were also produced to aid
the diagnostics. The original statistical analysis plan specified
the further use of linear trend analysis within the three dose
groups (i.e. excluding placebo). This was to examine dose–
response relationships and was based on the assumption that
the response would be an increasing function of dose. The
results clearly showed this assumption to be invalid, with the
maximum responses occurring in the medium-dose group.
Therefore, a quadratic trend analysis was added. This was the
only modification to the original analysis plan made after the
randomization scheme was revealed.
Ordinal data (parents’ and investigators’ assessments of
functional response and overall efficacy) were analyzed by
logistic regression. A similar model of treatment, baseline,
and centre was used as for the continuous variables. The p
value for the odds ratio of each of the treatment comparisons
was taken as an indication of the statistical significance of
results.
All hypothesis tests were two-sided and performed using a
5% level of significance. For each of the analyses performed
the data were examined for interactions. The effect of adding
treatment by centre and treatment by covariate interactions
into the model was assessed. If interactions were found to be
statistically significant at the 10% level (p<0.10), additional
covariates were included in the model, to remove the inter-
actions. If the interactions were not statistically significant at
this level, they were dropped from the model. The baseline
stratified dynamic component was included as a covariate in
all models because it was used as a stratification variable in
the randomization.
Results
PARTICIPANTS
A total of 126 participants were recruited to the study across
the 12 centres, of whom 124 completed the 16-week assess-
ment. One of these (in the 30 units/kg group) withdrew before
treatment and was excluded from the analyses, and another
(20 units/kg) was lost to follow-up after the visit in week 8.
BASELINE DATA
The details of patient demography are presented in Table I.
Baseline dynamic component and GMFM data are incorporated
in Tables II and III respectively. The treatment groups were well
matched with regard to age, sex, race, weight, and height.
ASSESSMENT OF EFFICACY
Electrogoniometry
Patients treated with placebo demonstrated only small changes
in the dynamic component throughout the 16-week observa-
tion period (Table II and Figure 1). However, in the three
active treatment groups, reductions in the dynamic compo-
nent were observed at each time point (Table IV). For each
active treatment group the change from baseline at week 4
was statistically significantly different from the placebo group,
and a statistically significant quadratic trend analysis suggest-
ed that the greatest improvement was in the 20 units/kg group
(Table V). The differences between active treatment groups
and placebo were greatest at week 4 but were still evident for
the 20 units/kg group at week 16 (Table IV).
Table II includes a considerable number of statistical tests
and is thus susceptible to identification of false positives.
Table V gives more detailed information on the parameters
selected, before the randomization code had been broken, as
primary and secondary outcome variables. Variables measured
at different assessment times from those of the primary and
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Table I: Demographic data
Placebo Dysport Dysport Dysport
10 units/kg 20 units/kg 30 units/kg
n patients 31 36 28 30
Age, ya 5.5 (2.2) 5.4 (2.0) 4.9 (1.9) 4.8 (2.1)
Sex, male/female, % 55/45 64/36 46/54 47/53
Race, caucasian, % 97 94 100 97
Weight, kga 18.7 (4.7) 17.7 (4.4) 17.3 (4.2) 17.3 (4.5)
Height, ma 1.09 (0.13) 1.08 (0.16) 1.04 (0.13) 1.05 (4.5)
aData are presented as mean (SD).
Figure 1: Reduction in dynamic component as measured at 4,
8, and 16 weeks. All values are expressed as % of muscle
length in anatomical position. Error bars represent standard
deviations.
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secondary outcome variables generally show commensurate
patterns, giving some confidence that these are genuine pos-
itive outcomes.
By definition, changes in dynamic component must be
reflected in changes in gastrocnemius muscle length.
Maximum passive gastrocnemius length changed little after
treatment, and no between-group differences were statisti-
cally significant. However, maximum active gastrocnemius
length increased in each active treatment group (Table II).
The greatest change from baseline was observed at week 4
but was still evident at week 16. Increases in active gastrocne-
mius length at week 4 for the 20 and 30 units/kg groups were
statistically significantly different from those in the placebo
group, but the increase observed in the 10 units/kg group
failed to reach statistical significance.
Passive ankle dorsiflexion changed little after treatment
(Table II) except in the 30 units/kg group, which demonstrat-
ed small but statistically significant increases with the knee
extended and flexed.
Figure 2 shows the result of the model to propose a more
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Table II: Electrogoniometry assessments
Placebo Dysport Dysport Dysport
group 10 units/kg 20 units/kg 30 units/kg
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Dynamic component, %
Baseline 56 3.4 (1.9) 68 3.2 (1.7) 55 3.4 (1.7) 56 3.3 (1.8)
Week 4 54 3.3 (1.9) 66 2.3 (1.7) 50 1.6 (1.4) 58 2.0 (1.7)
Week 8 57 3.5 (1.7) 64 2.9 (1.5) 50 2.2 (1.2) 59 2.7 (1.9)
Week 16 57 3.2 (1.7) 70 2.7 (1.6) 49 2.2 (1.4) 57 3.0 (1.9)
Change from baseline
Week 4 49 –0.38 (1.43) 65 –0.86 (1.14)a 50 –1.84 (2.07)c 54 –1.21 (1.60)b
Week 8 55 –0.11 (1.52) 67 –0.45 (1.36) 55 –1.23 (1.96)c 56 –0.51 (1.19)
Week 16 56 –0.24 (1.38) 68 –0.58 (1.38) 55 –1.20 (1.77)c 56 –0.28 (1.26)
Maximum active gastrocnemius length, %
Baseline 56 96.8 (2.7) 68 97.5 (2.4) 55 97.1 (2.3) 58 97.1 (2.4)
Week 4 54 96.8 (3.0) 66 98.3 (2.4) 50 99.1 (1.7) 58 98.2 (2.6)
Week 8 57 97.0 (2.6) 64 98.1 (2.5) 50 98.9 (1.8) 59 98.0 (2.3)
Week 16 57 96.8 (2.6) 70 97.9 (2.3) 49 98.4 (1.8) 57 97.3 (2.6)
Change from baseline
Week 4 49 0.2 (1.7) 65 0.7 (1.5) 50 2.1 (2.3)c 54 1.3 (1.8)b
Week 8 55 0.4 (1.9) 67 0.8 (1.7) 55 1.7 (2.4) 56 0.8 (1.6)
Week 16 56 0.0 (1.9) 68 0.5 (1.5) 55 1.4 (2.0) 56 0.2 (1.8)
Maximum passive gastrocnemius length, %
Baseline 56 100.2 (1.9) 68 100.7 (1.6) 55 100.5 (1.4) 56 100.3 (2.0)
Week 4 54 100.1 (2.1) 66 100.6 (1.8) 50 100.7 (1.0) 58 100.3 (1.8)
Week 8 57 100.6 (2.0) 64 101.1 (1.9) 50 101.1 (1.5) 59 100.7 (2.0)
Week 16 57 100.0 (1.9) 70 100.6 (1.7) 49 100.5 (1.3) 57 100.2 (1.9)
Change from baseline
Week 4 49 –0.2 (1.8) 65 –0.2 (1.6) 50 0.2 (1.6) 54 0.1 (1.6)
Week 8 55 0.3 (1.89) 67 0.4 (1.6) 55 0.5 (1.7) 56 0.2 (1.6)
Week 16 56 –0.2 (1.9) 68 0.0 (1.5) 55 0.2 (1.6) 56 –0.1 (1.6)
Passive ankle dorsiflexion with knee extended, °
Baseline 55 8.1 (15.0) 66 10.1 (12.7) 55 14.0 (17.2) 56 9.4 (19.4)
Week 4 50 8.2 (15.6) 62 10.2 (13.0) 50 13.7 (15.7) 56 10.1 (15.9)
Week 8 53 7.9 (14.6) 60 12.0 (14.1) 50 12.4 (15.6) 57 10.9 (14.4)
Week 16 59 4.1 (13.6) 69 9.7 (14.1) 49 11.6 (12.9) 57 9.0 (14.7)
Change from baseline
Week 4 46 –0.6 (13.5) 61 –0.5 (10.8) 50 –0.6 (16.3) 53 2.6 (14.4)a
Week 8 52 –1.6 (12.6) 63 –0.1 (11.6) 55 –2.2 (16.7) 55 2.7 (14.0)
Week 16 55 –2.8 (14.9) 66 –0.9 (12.3) 55 –2.2 (13.2) 56 0.9 (16.2)
Passive ankle dorsiflexion with knee flexed,˚
Baseline 55 21.4 (14.3) 66 25.3 (14.3) 55 24.3 (17.7) 56 21.2 (18.2)
Week 4 50 22.6 (15.4) 62 25.9 (13.9) 50 26.4 (17.0) 56 23.4 (16.7) 
Week 8 53 24.3 (12.6) 60 27.0 (14.1) 50 26.3 (17.4) 57 24.6 (13.9)
Week 16 59 16.4 (13.3) 70 23.7 (12.9) 49 24.3 (15.9) 57 20.9 (15.7)
Change from baseline
Week 4 46 –1.0 (13.7) 61 0.2 (10.8) 50 1.0 (16.1) 53 4.4 (11.5)a
Week 8 52 0.1 (11.5) 63 –0.7 (12.0) 55 0.6 (15.0) 55 5.0 (11.6)
Week 16 55 –4.4 (14.4) 66 –2.3 (11.5) 55 –0.1 (14.0) 56 0.8 (13.0)
ap<0.05, bp<0.01, cp<0.001. All comparisons are between active treatment group and placebo group.
clinically meaningful way of describing changes in dynamic
component. It can be seen that the equivalent increase in
dorsiflexion with the knee extended is very nearly propor-
tional to the increase in dynamic component and, therefore,
can be used as an alternative method for presenting results.
Each 1% increase in dynamic component is equivalent to the
participant having an extra 10.6° of dorsiflexion available
while walking. For dynamic components of less than 5% this
approximation is accurate to within 1.2˚ for participants
with heights in the range 500 to 1500mm.
Gross motor function measurement
Neither the overall nor the goal total GMFM scores showed
statistically different changes at either 4 or 16 weeks.
Consideration of the mean changes at week 4 (Table III and
Fig. 3) suggests a small placebo response. At week 16 the
scores for the placebo group had not increased further.
However, the scores for the active treatment groups at week
16 had increased further, especially in the higher dose groups.
Subjective assessments of benefit
The subjective assessments of functional benefit demonstrat-
ed substantial agreement between the parents and investiga-
tors (Table IV). For all active treatment groups the proportion
of patients demonstrating a good response was markedly
higher than in the placebo group at all time points. Despite
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Table III: Gross motor function measurement
Placebo Dysport Dysport Dysport
group 10 units/kg 20 units/kg 30 units/kg
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Overall score, %
Baseline 31 70 (17) 35 73 (19) 27 71 (20) 30 69 (22)
Week 4 30 73 (16) 35 76 (19) 26 74 (19) 30 70 (22)
Week 16 31 73 (17) 35 77 (18) 26 75 (18) 30 73 (21)
Change from baseline
Week 4 30 2.5 (4.7) 35 2.5 (3.1) 26 1.4 (4.2) 30 1.3 (9.3)
Week 16 31 2.3 (10.4) 35 3.8 (4.2) 26 4.4 (5.4) 30 4.5 (5.8)
Goal total score, %
Baseline 31 45 (26) 35 52 (29) 27 51 (27) 30 47 (31)
Week 4 30 49 (27) 35 57 (29) 26 53 (27) 30 50 (31)
Week 16 31 49 (26) 35 58 (29) 26 55 (26) 30 53 (32)
Change from baseline
Week 4 30 4.1 (4.3) 35 4.3 (4.1) 26 2.1 (6.7) 30 3.3 (9.4)
Week 16 31 4.1 (8.9) 35 5.7 (6.0) 26 5.9 (8.1) 30 6.3 (7.5)
Scores are presented as a percentage of maximum score possible (100%).
Figure 2: Increase in dorsiflexion with knee extended
equivalent to a given change in dynamic component using
model of Eames et al. (1999).
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Figure 3: Change from baseline in GMFM overall score at 4
and 16 weeks. All score expressed as % of total possible
score. Error bars represent standard deviations.
these marked differences, only those for the 30 units/kg group
at week 4 (parent and investigator) and the 20 units/kg
group at week 16 (investigator) reached statistical significance
(Table V).
The overall assessment of efficacy (Table IV) found that
over three-quarters of parents and investigators considered
Dysport treatment to be of benefit to the patient, with the
parent’s assessment of the 30 units/kg group demonstrating
statistical significance compared with placebo.
ASSESSMENT OF SAFETY
A total of 48 of 94 (51%) Dysport-treated patients reported
123 adverse events, compared with 10 of 31 (32%) placebo
patients, who reported 20 adverse events. In all treatment
groups most adverse events were considered mild (placebo,
12 of 20 [60%]; Dysport, 85 of 123 [69%]), and most resolved
within 2 weeks of onset (placebo, 14 of 20 [70%]; Dysport,
89 of 123 [72%]). No patient withdrew as a result of an
adverse event. Table VI presents the overall adverse event
profile for the study.
It would be expected, from the known pharmacodynamic
properties of Dysport, that most drug-related effects would
be evident within 4 weeks of treatment (Scott 1981). Although
similar proportions of all reported adverse events occurred
during this period for placebo-treated (7 of 20 [35%]) and
Dysport-treated patients (44 of 123 [36%]), the adverse event
profile for Dysport-treated patients was notably different
from the overall profile, with pain (6%), falls (5%), and asthe-
nia (4%) being the most frequently reported.
Analysis of the adverse events considered to be related 
to study medication also produced a different profile. No
adverse event reported by the placebo group was considered
to be related to study medication, whereas 29 of 123 (24%)
adverse events reported by Dysport-treated patients were
considered to be related to study medication. The adverse
events most frequently considered to be related to study med-
ication were falls (n=6), pain (n=6), and asthenia (n=4).
Table VI also presents the adverse event profiles for each
dose group. Similar proportions of patients in the 10 units/kg
group (21 of 36 patients [58%]) and the 30 units/kg group (17
of 30 patients [57%]) reported at least one adverse event, but
this proportion was lower in the 20 units/kg group (10 of 28
[36%]). In terms of the number of adverse events reported by
these patients, the 30 units/kg group reported the most, with
an average of 3.2 events per patient. This was higher than in the
two lower-dose groups (10 units/kg, 2.2 events per patient; 20
units/kg, 2.3 events per patient). There were no statistically sig-
nificant differences between placebo and any active treatment
group for any individual adverse event category.
Discussion
This double-blind placebo-controlled study has demonstrat-
ed a clear improvement in the dynamic component in
patients with diplegic CP after treatment with BTX-A, in
agreement with the findings of Eames et al. (1999). Because
gastrocnemius muscle length is expressed as a percentage of
the normal length with the leg in the anatomical position,
and the dynamic component is defined as the difference
between passive and active muscle lengths, the change in
dynamic component is difficult to interpret clinically.
However, with the use of the simple model represented by
Figure 3 we can equate the 1.8% change in dynamic compo-
nent for children receiving Dysport at 20 units/kg to an extra
19˚ of available dorsiflexion with the knee extended, but it
should be noted that this equivalence is a purely theoretical
construct representing how much extra dorsiflexion the par-
ticipant would have if the knee were fully extended during
stance: it does not actually require the participant to achieve
this. It is also essentially a measure of the change in the length
of the muscle while walking and, therefore, does not imply
that the extra dorsiflexion should be observed on passive
examination. Indeed, the changes observed in the dynamic
component were due almost entirely to increases in the
length of the gastrocnemius during gait.
One unexpected finding of this study was that the change
in dynamic component in the group receiving Dysport at 30
units/kg was less than that observed in the 20 units/kg group.
It is only possible to speculate on the likely reason for this. It
might be that the toxin spreads locally. The injection volume
was constant for all doses, so it is likely that perfusion was
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Table IV: Subjective assessments of benefit
Placebo Dysport Dysport Dysport
10 units/kg 20 units/kg 30 units/kg
Parents’ assessment of functional response to treatment
Week 4 (total) 31 36 27 30
Good 7 16 12 16b
Minimal 14 12 9 11
None 9 8 4 2
Worse 1 0 2 1
Week 8 (total) 31 34 28 30
Good 8 13 12 13
Minimal 13 11 10 14
None 10 10 5 1
Worse 0 0 1 2
Week 16 (total) 31 36 27 30
Good 6 12 9 8
Minimal 11 15 10 13
None 14 9 7 8
Worse 0 0 1 1
Investigators’ assessment of functional response to treatment
Week 4 (total) 30 36 27 30
Good 7 16 11 11a
Minimal 12 12 9 16
None 11 8 7 2
Worse 0 0 0 1
Week 8 (total) 31 34 28 30
Good 5 13 10 12
Minimal 16 13 11 13
None 10 8 7 4
Worse 0 0 0 1
Week 16 (total) 31 36 27 30
Good 6 9 10 a 6
Minimal 11 14 10 15
None 14 13 7 8
Worse 0 0 0 1
Treatment considered to be of benefit at overall assessment of efficacy
Parent 31 18 36 28 27 21 30 25a
Investigator 31 20 36 28 27 22 29 24
Results are numbers of participants. ap<0.05, bp<0.01.
similar. It might only be at high doses, however, that the
effect on other muscles becomes appreciable. Weakening of
the soleus in particular might result in a more crouched gait
pattern (this phenomenon is a recognized complication of
surgical lengthening of the tendo-Achilles).
If the body weight is to remain in the same position above
the base of support, then for every degree of increased dorsi-
flexion there must be approximately 2˚ of increased knee
flexion. In this event, because the increase in knee flexion is
greater than that in ankle dorsiflexion, the length between
gastrocnemius origin and insertion will reduce. Thus, even
though the gastrocnemius might be similarly weakened in
the 30 and 20 units/kg groups, the recorded active muscle
length would be lower in the 30 units/kg group and the
reduction in dynamic component would not be as marked.
Weakening of any of the extensor muscles might have this
effect but the soleus, being so close to the gastrocnemius, is
assumed to be the most likely to be affected.
If this analysis is correct, the relaxed gastrocnemius muscle
was not being subjected to as great a stretch during walking
in the 30 units/kg group. According to the hypothesis of Holly
and coworkers (1980) that muscle growth is stimulated by
passive stretching, it can be expected that the duration of the
effect of the toxin might be reduced if the degree of stretch is
reduced. It can indeed be seen (Table II and Fig. 1) that at 16
weeks after treatment with Dysport 20 units/kg, the mean
dynamic component remained at 65% of that observed at the 4-
week assessment, whereas the mean value for the 30 units/kg
group had fallen to 23% of the initial response. Indeed, by 16
weeks the response in the 30 units/kg group was indistinguish-
able from that in the placebo group.
The raw data on ankle and knee angle were re-analyzed to
examine the hypothesis that the 30 units/kg group showed
greater knee flexion and dorsiflexion, but the data showed
large variability and, although trends were apparent, statistical
significance was not achieved. Therefore, the above explana-
tion must remain hypothetical. Despite much consideration
of this issue we are unable to suggest any alternative. Whatever
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Table V: Differences from placebo group for primary and secondary outcome variables
Time Units Dysport Dysport Dysport Linear trend Quadratic trend
(weeks) 10 units/kg 20 units/kg 30 units/kg
Primary outcome measure
Dynamic component 4 % anat. length –0.6 –1.5 –1.2 ns p=0.009
(–1.2, 0.0) (–2.0, –0.8) (–1.5, –0.3) p=0.303
p=0.046f p<0.001f p=0.004f
Secondary outcome measures
Max. passive dorsiflexion 4 Degrees 2.8 4.5 4.6 ns ns
(knee extension) (–1.5, 7.2) (0.0, 9.1) (–0.1, 9.0) p=0.416 p=0.679
p=0.192f p=0.052f p=0.043f
Max. passive dorsiflexion 4 Degrees 2.3 2.3 6.3 ns ns
(knee flexion) (–2.8, 7.4) (–3.1, 7.6) (1.0, 11.5) p=0.112 p=0.368
p=0.373f p=0.404f p=0.019f
GMFM (overall score) 4 % 0.2 –1.2 –1.6 N/A N/A
(–2.8, 3.2) (–4.5, 2.0) (–4.7, 1.6)
p=0.877f p=0.448f p=0.326f
GMFM (goal score) 4 % 0.2 –1.7 –1.2 N/A N/A
(–3.1,3.5) (–5.3, 1.8) (–5.3, 1.8)
p=0.900f p=0.335f p=0.472f
Subjective functional 4 Odds ratio 1.9 1.9 4.0 ns ns
assessment (parent) (0.8, 5.1) (0.7, 5.3) (1.4, 11.3) p=0.162 p=0.397
p=0.160t p=0.215t p=0.009t
Subjective functional 4 Odds ratio 2.5 2.2 3.3 ns ns
assessment (investigator) (0.92, 6.6) (0.78, 6.5) (1.2, 9.4) p=0.571 p=0.609
p=0.073t p=0.135t p=0.026t
Overall assessment of  16 Odds ratio 0.4 0.4 0.2 ns ns
efficacy (parent) (0.1, 1.2) (0.1, 1.6) (0.1, 0.9) p=0.527 p=0.594
p=0.099t p=0.194t p=0.039t
Overall assessment of 16 Odds ratio 0.4 0.3 0.3 N/A N/A
efficacy (investigator) (0.1, 1.5) (0.1, 1.2) (0.1, 1.2)
p=0.174t p=0.093t p=0.093t
f f-statistic; t t-statistic.
Figures shown are a treatment comparison adjusting for effects of baseline, centre, and baseline stratified dynamic component. 
Data are presented as mean values, 95% confidence limits, and p values for statistical significance (f-statistic for continuous variables analyzed
with analysis of covariance, t-statistic for categorical data analyzed on basis of odds ratio).
GMFM, Gross Motor Function Measure; N/A, not analyzed. Linear and quadratic trend analyses were conducted only if at least one treatment
group showed a statistically significant treatment effect at p<0.05.
the explanation, it is clear that the magnitude and duration of
effects in the 30 units/kg group are lower than those in the 20
units/kg group and that an optimal dose does exist.
At 4 weeks after treatment, overall GMFM scores were sim-
ilar in each of the treatment groups, and all were slightly
higher than baseline (Fig. 3). The score for the placebo group
had not increased further by week 16, suggesting that the ear-
lier increase could be due to some learning effect. In con-
trast, the scores for the active treatment groups continued to
increase, with the greatest increases observed in the higher-
dose groups, suggesting that functional benefit can be main-
tained at least until week 16. It is possible that the initial
gastrocnemius muscle weakening has an adverse impact on
motor function. However, although this direct effect of the
toxin on the muscle occurs over a number of days, it would be
expected that it would take considerably longer for children
to learn how to build on these changes to improve gross
motor function. Thus it is probable that the changes observed
at 16 weeks after treatment result from a reduced weakening
of the muscle in combination with newly learnt changes in
motor function on the part of the patients themselves.
However, caution should be used when drawing conclu-
sions from the GMFM data because no between-group differ-
ences reached statistical significance, possibly owing to low
patient numbers. It is also possible that the GMFM is not sen-
sitive enough to detect the functional improvements that
were subjectively reported in this study. The GMFM is
designed to assess whether patients can perform various
functions but does not assess how well each function is per-
formed. It is, therefore, unable to detect improvements in
the quality of function.
A notable aspect of the subjective assessments of efficacy
is the sizeable proportion of patients in the placebo group
who were considered to have demonstrated a good response
to treatment. Although such subjective assessments have a
place in clinical research, this study indicates the potential
for misinterpretation and demonstrates the importance of
incorporating an appropriate control group. Despite checks
to try and ensure independence of assessors’ and parents’
opinions, it is almost certain that there is some influence of
one on the other and the importance of differences or simi-
larities in these data should not be over interpreted.
This study has also demonstrated that the doses of
Dysport used in this study were safe in the population of
patients studied. The few reports of possible toxin-related
adverse events such as calf pain and increased frequency of
falls (due to leg muscle weakness) were mild and transient,
and could probably be minimized in clinical practice by
appropriate dose titration.
In conclusion, this study has demonstrated that Dysport
(10 to 30 units/kg) is safe and effective in the treatment of
paediatric dynamic equinus spasticity associated with CP.
From the evidence presented, it is reasonable to conclude
that a dose of 20 units/kg would be an optimal starting dose.
The effects had started wearing off by 16 weeks but were still
clearly present.
Accepted for publication 31st May 2002.
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Table VI: Adverse event incidence
Placebo All Dysport Dysport Dysport Dysport
groups 10 units/kg 20 units/kg 30 units/kg
Patients 31 94 36 28 30
Patients with adverse events 10 48 21 10 17
Pharyngitis 1 9 5 1 3
Fever 3 8 5 2 1
Pain 2 8 4 0 4
Falls 0 7 1 3 3
URTI 0 6 2 2 2
Infection 1 6 2 2 2
Bronchitis 0 5 3 1 1
Viral infection 0 5 4 0 1
Asthenia 0 4 0 2 2
Asthma 0 4 1 1 2
Cough increased 4 4 4 0 0
Convulsion 2 4 2 0 2
Vomiting 0 4 2 2 0
Cold 1 3 1 2 1
Diarrhoea 0 3 2 1 0
Gastroenteritis 0 2 0 0 2
Somnolence 0 2 0 0 2
Adverse events 20 123 46 23 54
Adverse events per patient 2.0 2.6 2.2 2.3 3.2
Adverse event incidence is presented as number of patients reporting each adverse event. Adverse events are
categorized by COSTART (US Food and Drug Administration, Center for Drug Evaluation and Research 1995)
preferred term and only those reported by at least two patients in any treatment group are presented. URTI, upper
respiratory tract infection.
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